Manchester and London, UK, 4 September, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced positive initial data from its Orexin-1 programme to treat stress-related addictive disorders, and the filing of a related patent.

Manchester and London, UK, 26 August, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has signed a research collaboration agreement with Takeda Cambridge Limited ("TCB"), a UK subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. Under the agreement, C4XD's proprietary NMR-based technology will be applied across a number of TCB's therapeutic projects to enhance lead discovery and hit identification.

Manchester and London, UK, 4 July, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced that its patent relating to a new method for determining the three-dimensional structures of dynamic molecules has been granted in Japan.

Manchester and London, UK, 4 July, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced that it has won a grant from the UK's innovation agency, the Technology Strategy Board.

Manchester and London, UK, 24 June, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced the publication of a new peer-reviewed paper in the Journal of Medicinal Chemistry (“JMedChem”). JMedChem is published by the American Society of Chemistry and is widely regarded as one of the leading publications for research and development. The paper was co-authored with researchers from C4XD’s collaboration partner, AstraZeneca, and Pharmaron Beijing Co Ltd.

Manchester and London, UK, 11 June, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced the appointment of Piers Morgan as Chief Executive Officer with immediate effect. Mr Morgan has also been appointed to the Company's Board of Directors. He succeeds Dr Sam Williams, who returns to his previous role as a Non-Executive Director of the Company.

Technology emerging as a valuable tool for designing new medicines

Manchester, UK, November 10 2013 – C4X Discovery (C4XD), a leader in conformational drug discovery and design, announces the publication of a new peer-reviewed paper in Drug Discovery Today examining the use of its technology in structure-based drug design¹. This paper follows the recent publication of the first peer-reviewed description of C4XD’s technology in Bioorganic & Medicinal Chemistry².

C4XD technology to drive rational design of new drug candidates for HIV

Manchester, UK, September 23 2013 – C4X Discovery (C4XD), a leader in conformational drug discovery and design, is to collaborate with the University of Southampton on rational design of novel drug candidates derived from cyclic peptides. Led by Dr Ali Tavassoli, a world expert in this area^1,2, researchers at the University have discovered new blockers³ of a protein-protein interaction in viral budding, a key step in the process by which HIV spreads in the body. The partners will use C4XD's 4D NMR technology to analyse the active confirmation of the inhibitors, with this enhanced understanding of activity leading to optimised second-generation compounds with more drug-like properties.